Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients

Objectives: Fetuin-A, a glycoprotein with several functions, is also a negative acute phase reactant. The purpose of this study was to investigate levels of serum fetuin-A in coronavirus disease 2019 (COVID-19) patients, its association with disease severity, and whether it has superiority over C-reactive protein (CRP). Methods: The research comprised 56 individuals with COVID-19(+) and 30 healthy controls. The COVID-19(+) patient population was split into three subgroups: mild, moderate, and severe. All participants’ serum concentrations of fetuin- A, tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) were measured using ELISA commercial test kits. In addition, CRP and other biochemical values from biochemistry laboratory data were gathered, and the CRP/fetuin-A ratio was calculated. Results: The fetuin-A concentration of the COVID-19(+) patient group was shown to be statistically lower than that of the healthy control group. TNF-α and IL-6 levels were found to be significantly different in both groups. While fetuin-A had a higher area under the curve (AUC) value than CRP (0.875 and 0.800, respectively), CRP/fetuin-A had the strongest AUC (0.933). Conclusion: Low serum fetuin-A concentrations in COVID-19 patients suggest that fetuin-A is a negative acute phase reactant for severe acute respiratory syndrome coronavirus 2. Furthermore, fetuin-A alone and CRP/fetuin-A value are both contenders for being more remarkable markers than CRP.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Bulut C, Kato Y. Epidemiology of covid-19. Turkish J Med Sci 2020;50:563–70.
2. Peiris JS, Lai ST, Poon LL, Guan Y, Yam LY, Lim W, et al; SARS study group. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003;361(9366):1319–25.
3. WHO. Report of the WHO-China joint mission on coronavirus disease 2019 (COVID-19). WHO-China Jt Mission Coronavirus Dis 2019 2020;1:1–40. Available at: https://www.who.int/publications/ i/item/report-of-the-who-china-joint-mission-oncoronavirus- disease-2019-(covid-19). Accessed Aug 29, 2022.
4. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020;323(13):1239–42.
5. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human alpha 2 HS glycoprotein during the inflammatory process: evidence that alpha 2 HS glycoprotein is a negative acute-phase reactant. J Clin Invest 1979;64(4):1118–29.
6. Daveau M, Christian-Davrinche, Julen N, Hiron M, Arnaud P, Lebreton JP. The synthesis of human alpha-2-HS glycoprotein is down-regulated by cytokines in hepatoma HepG2 cells. FEBS Lett 1988;241(1-2):191–4.
7. Yet MG, Chin CC, Wold F. The covalent structure of individual N-linked glycopeptides from ovomucoid and asialofetuin. J Biol Chem 1988;263(1):111–7.
8. Zhang M, Caragine T, Wang H, Cohen PS, Botchkina G, Soda K, et al. Spermine inhibits proinflammatory cytokine synthesis in human mononuclear cells: A counterregulatory mechanism that restrains the immune response. J Exp Med 1997;185(10):1759–68.
9. Ombrellino M, Wang H, Yang H, Zhang M, Vishnubhakat J, Frazier A, et al. Fetuin, a negative acute phase protein, attenuates TNF synthesis and the innate inflammatory response to carrageenan. Shock 2001;15(3):181–5.
10. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest 2003;112:299.
11. Pepys MB. C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target? Eur Heart J 2021;42(23):2280–3.
12. Lentner J, Adams T, Knutson V, Zeien S, Abbas H, Moosavi R, et al. C-reactive protein levels associated with COVID-19 outcomes in the United States. J Osteopath Med 2021;121(12):869–73.
13. Zhu X, Wang Y, Zhang H, Liu X, Chen T, Yang R, et al. Genetic variation of the human α-2-Heremans-Schmid glycoprotein (AHSG) gene associated with the risk of SARS-CoV infection. Plos One 2011;6(8):e23730.
14. Özgeriş FB, Kurt N, Ibili Ucuz I, Koçak Yilmaz K, Keleş MS, Çayir A, et al. Is serum progranulin level a biomarker in autism and cognitive development disorders? Eurasian J Med 2022;54(1):50–3.
15. Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen- Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J 1996;9(8):1736–42.
16. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020;92(7):797–806.
17. Feng X, Li S, Sun Q, Zhu J, Chen B, Xiong M, et al. Immuneinflammatory parameters in COVID-19 cases: A systematic review and meta-analysis. Front Med (Lausanne) 2020;7:301.
18. Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis 2020;95:332–9.
19. Jones SA, Hunter CA. Is IL-6 a key cytokine target for therapy in COVID-19? Nat Rev Immunol 2021;21(6):337–9.
20. Udomsinprasert W, Jittikoon J, Sangroongruangsri S, Chaikledkaew U. Circulating levels of interleukin-6 and interleukin- 10, but not tumor necrosis factor-alpha, as potential biomarkers of severity and mortality for COVID-19: Systematic review with meta-analysis. J Clin Immunol 2021;41(1):11–22.
21. Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L, et al. SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol 2020;73(4):807–16.
22. Vinken M. COVID-19 and the liver: an adverse outcome pathway perspective. Toxicology 2021;455:152765.
23. Weikert C, Stefan N, Schulze MB, Pischon T, Berger K, Joost HG, et al. Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 2008;118(24):2555–62.
24. Li W, Zhu S, Li J, Huang Y, Zhou R, Fan X, et al. A hepatic protein, fetuin-A, occupies a protective role in lethal systemic inflammation. Plos One 2011;6(2):e16945.
25. Kukla M, Menżyk T, Dembiński M, Winiarski M, Garlicki A, Bociąga-Jasik M, et al. Fetuin-a deficiency but not pentraxin 3, FGF-21, or irisin, predisposes to more serious COVID-19 course. Biomolecules 2021;11(10):1422

APA	KURT N, OZGERIS F, KOCAK O, Yüce N, bayraktutan z, PARLAK E, ÇOBAN T, Bakan E (2022). Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. , 125 - 131. 10.14744/ijmb.2022.83097
Chicago	KURT Nezahat,OZGERIS FATMA BETÜL,KOCAK OMER FARUK,Yüce Neslihan,bayraktutan zafer,PARLAK EMİNE,ÇOBAN T. Abdulkadir,Bakan Ebubekir Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. (2022): 125 - 131. 10.14744/ijmb.2022.83097
MLA	KURT Nezahat,OZGERIS FATMA BETÜL,KOCAK OMER FARUK,Yüce Neslihan,bayraktutan zafer,PARLAK EMİNE,ÇOBAN T. Abdulkadir,Bakan Ebubekir Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. , 2022, ss.125 - 131. 10.14744/ijmb.2022.83097
AMA	KURT N,OZGERIS F,KOCAK O,Yüce N,bayraktutan z,PARLAK E,ÇOBAN T,Bakan E Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. . 2022; 125 - 131. 10.14744/ijmb.2022.83097
Vancouver	KURT N,OZGERIS F,KOCAK O,Yüce N,bayraktutan z,PARLAK E,ÇOBAN T,Bakan E Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. . 2022; 125 - 131. 10.14744/ijmb.2022.83097
IEEE	KURT N,OZGERIS F,KOCAK O,Yüce N,bayraktutan z,PARLAK E,ÇOBAN T,Bakan E "Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients." , ss.125 - 131, 2022. 10.14744/ijmb.2022.83097
ISNAD	KURT, Nezahat vd. "Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients". (2022), 125-131. https://doi.org/10.14744/ijmb.2022.83097

APA	KURT N, OZGERIS F, KOCAK O, Yüce N, bayraktutan z, PARLAK E, ÇOBAN T, Bakan E (2022). Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. International Journal of Medical Biochemistry, 5(3), 125 - 131. 10.14744/ijmb.2022.83097
Chicago	KURT Nezahat,OZGERIS FATMA BETÜL,KOCAK OMER FARUK,Yüce Neslihan,bayraktutan zafer,PARLAK EMİNE,ÇOBAN T. Abdulkadir,Bakan Ebubekir Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. International Journal of Medical Biochemistry 5, no.3 (2022): 125 - 131. 10.14744/ijmb.2022.83097
MLA	KURT Nezahat,OZGERIS FATMA BETÜL,KOCAK OMER FARUK,Yüce Neslihan,bayraktutan zafer,PARLAK EMİNE,ÇOBAN T. Abdulkadir,Bakan Ebubekir Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. International Journal of Medical Biochemistry, vol.5, no.3, 2022, ss.125 - 131. 10.14744/ijmb.2022.83097
AMA	KURT N,OZGERIS F,KOCAK O,Yüce N,bayraktutan z,PARLAK E,ÇOBAN T,Bakan E Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. International Journal of Medical Biochemistry. 2022; 5(3): 125 - 131. 10.14744/ijmb.2022.83097
Vancouver	KURT N,OZGERIS F,KOCAK O,Yüce N,bayraktutan z,PARLAK E,ÇOBAN T,Bakan E Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients. International Journal of Medical Biochemistry. 2022; 5(3): 125 - 131. 10.14744/ijmb.2022.83097
IEEE	KURT N,OZGERIS F,KOCAK O,Yüce N,bayraktutan z,PARLAK E,ÇOBAN T,Bakan E "Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients." International Journal of Medical Biochemistry, 5, ss.125 - 131, 2022. 10.14744/ijmb.2022.83097
ISNAD	KURT, Nezahat vd. "Evaluation of fetuin-A, CRP, and CRP/fetuin-A values in COVID-19 patients". International Journal of Medical Biochemistry 5/3 (2022), 125-131. https://doi.org/10.14744/ijmb.2022.83097